Treatment with Tumor-infiltrating Lymphocytes in Advanced Melanoma Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Melanie A. Lindenberg, Valesca P. Retl, Joost H. van den Berg, Marnix H. Geukes Foppen, John B. Haanen, Wim H. Van Harten* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
38 Downloads (Pure)

Abstract

Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a European setting, TIL-therapy has been in use since 2011 and is currently being evaluated in a randomized controlled trial. As clinical implementation of ATMPs is challenging, this study aims to evaluate early application of TIL-therapy, through the application of a constructive technology assessment (CTA). First the literature on ATMP barriers and facilitators in clinical translation was summarized. Subsequently, application of TILtherapy was evaluated through semistructured interviews with 26 stakeholders according to 6 CTA domains: clinical, economic, patient-related, organizational, technical, and future. In addition, treatment costs were estimated. A number of barriers to clinical translation were identified in the literature, including: inadequate financial support, lack of regulatory knowledge, risks in using live tissues, and the complex path to market approval. Innovative reimbursement procedures could particularly facilitate translation. The CTA survey of TIL-therapy acknowledged these barriers, and revealed the following facilitators: the expected effectiveness resulting in institutional support for an internal pilot, the results of which led to the inclusion of TIL-therapy in a national coverage

Original languageEnglish
Pages (from-to)413-425
Number of pages13
JournalJournal of Immunotherapy
Volume41
Issue number9
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Tumor-Infiltrating Lymphocytes
Melanoma
Biomedical Technology Assessment
Therapeutics
Financial Support
Health Care Costs
Randomized Controlled Trials
Economics
Interviews

Keywords

  • UT-Hybrid-D
  • Advanced therapy medicinal product
  • Malignant melanoma
  • Translational medical research
  • Tumor-infiltrating lymphocytes
  • Adoptive immunotherapy

Cite this

@article{5e95347dbb0c41d2ae0c88deeb7206b7,
title = "Treatment with Tumor-infiltrating Lymphocytes in Advanced Melanoma Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product",
abstract = "Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a European setting, TIL-therapy has been in use since 2011 and is currently being evaluated in a randomized controlled trial. As clinical implementation of ATMPs is challenging, this study aims to evaluate early application of TIL-therapy, through the application of a constructive technology assessment (CTA). First the literature on ATMP barriers and facilitators in clinical translation was summarized. Subsequently, application of TILtherapy was evaluated through semistructured interviews with 26 stakeholders according to 6 CTA domains: clinical, economic, patient-related, organizational, technical, and future. In addition, treatment costs were estimated. A number of barriers to clinical translation were identified in the literature, including: inadequate financial support, lack of regulatory knowledge, risks in using live tissues, and the complex path to market approval. Innovative reimbursement procedures could particularly facilitate translation. The CTA survey of TIL-therapy acknowledged these barriers, and revealed the following facilitators: the expected effectiveness resulting in institutional support for an internal pilot, the results of which led to the inclusion of TIL-therapy in a national coverage",
keywords = "UT-Hybrid-D, Advanced therapy medicinal product, Malignant melanoma, Translational medical research, Tumor-infiltrating lymphocytes, Adoptive immunotherapy",
author = "Lindenberg, {Melanie A.} and Retl, {Valesca P.} and {van den Berg}, {Joost H.} and {Geukes Foppen}, {Marnix H.} and Haanen, {John B.} and {Van Harten}, {Wim H.}",
note = "Lippincott WW deal",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/CJI.0000000000000245",
language = "English",
volume = "41",
pages = "413--425",
journal = "Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

Treatment with Tumor-infiltrating Lymphocytes in Advanced Melanoma Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. / Lindenberg, Melanie A.; Retl, Valesca P.; van den Berg, Joost H.; Geukes Foppen, Marnix H.; Haanen, John B.; Van Harten, Wim H. (Corresponding Author).

In: Journal of Immunotherapy, Vol. 41, No. 9, 01.11.2018, p. 413-425.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Treatment with Tumor-infiltrating Lymphocytes in Advanced Melanoma Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

AU - Lindenberg, Melanie A.

AU - Retl, Valesca P.

AU - van den Berg, Joost H.

AU - Geukes Foppen, Marnix H.

AU - Haanen, John B.

AU - Van Harten, Wim H.

N1 - Lippincott WW deal

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a European setting, TIL-therapy has been in use since 2011 and is currently being evaluated in a randomized controlled trial. As clinical implementation of ATMPs is challenging, this study aims to evaluate early application of TIL-therapy, through the application of a constructive technology assessment (CTA). First the literature on ATMP barriers and facilitators in clinical translation was summarized. Subsequently, application of TILtherapy was evaluated through semistructured interviews with 26 stakeholders according to 6 CTA domains: clinical, economic, patient-related, organizational, technical, and future. In addition, treatment costs were estimated. A number of barriers to clinical translation were identified in the literature, including: inadequate financial support, lack of regulatory knowledge, risks in using live tissues, and the complex path to market approval. Innovative reimbursement procedures could particularly facilitate translation. The CTA survey of TIL-therapy acknowledged these barriers, and revealed the following facilitators: the expected effectiveness resulting in institutional support for an internal pilot, the results of which led to the inclusion of TIL-therapy in a national coverage

AB - Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a European setting, TIL-therapy has been in use since 2011 and is currently being evaluated in a randomized controlled trial. As clinical implementation of ATMPs is challenging, this study aims to evaluate early application of TIL-therapy, through the application of a constructive technology assessment (CTA). First the literature on ATMP barriers and facilitators in clinical translation was summarized. Subsequently, application of TILtherapy was evaluated through semistructured interviews with 26 stakeholders according to 6 CTA domains: clinical, economic, patient-related, organizational, technical, and future. In addition, treatment costs were estimated. A number of barriers to clinical translation were identified in the literature, including: inadequate financial support, lack of regulatory knowledge, risks in using live tissues, and the complex path to market approval. Innovative reimbursement procedures could particularly facilitate translation. The CTA survey of TIL-therapy acknowledged these barriers, and revealed the following facilitators: the expected effectiveness resulting in institutional support for an internal pilot, the results of which led to the inclusion of TIL-therapy in a national coverage

KW - UT-Hybrid-D

KW - Advanced therapy medicinal product

KW - Malignant melanoma

KW - Translational medical research

KW - Tumor-infiltrating lymphocytes

KW - Adoptive immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85054772740&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000245

DO - 10.1097/CJI.0000000000000245

M3 - Article

C2 - 30300260

AN - SCOPUS:85054772740

VL - 41

SP - 413

EP - 425

JO - Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy

JF - Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy

SN - 1524-9557

IS - 9

ER -